← VAST
An old molecule.
A wider field.
Everything beneath the surface of VAST — mescaline’s pharmacology, molecular identity, exact label arithmetic, primary human research and the safety that matters. The honest, in-depth version.
Controlled human studies used 100–800mg of mescaline hydrochloride. They do not validate a benefit, effect profile, schedule or safety claim for the 3mg-per-drop VAST format. The drop figures on this page are formulation arithmetic—not clinical guidance.
mediated by 5-HT2A.
In controlled human research, mescaline’s acute psychedelic effects were dose-dependent from 200mg and were strongly reduced by ketanserin, supporting 5-HT2A as the primary mechanism. The same study reported slow absorption and an elimination half-life of about 3.5 hours.
Slow oral absorption
Mescaline enters the bloodstream gradually. Controlled pharmacokinetic work links its extended acute profile in part to slower absorption rather than an unusually long elimination half-life alone.
5-HT2A activation
Mescaline acts as a classic serotonergic psychedelic. Ketanserin, a 5-HT2A antagonist, strongly reduced acute effects in a placebo-controlled study.
Dose-dependent response
At 100–800mg, subjective effects and autonomic measures changed with dose. Those results cannot be scaled down into a reliable effect claim for very-low-dose use.
A longer clinical arc
In one controlled comparison, mescaline’s average acute effect duration was 11.1 hours, longer than LSD at 8.2 hours and psilocybin at 4.9 hours under the study conditions.
The unanswered low-dose question
There is not yet controlled human evidence defining benefits, impairment, ideal frequency or a reliable subjective threshold for the VAST label format.
precisely.
Mescaline is a naturally occurring phenethylamine. Sharing a psychedelic category with LSD and psilocybin does not make their potency, timing or risk interchangeable.
can—and cannot—say.
The VAST system uses 150mg/mL in a 10mL vial, with approximately 500 nominal drops. If the final device delivers 0.02mL per drop, the arithmetic resolves to 3mg per drop.
What must still be proven: actual fill volume, homogeneity, stability, drop mass or volume distribution, delivered content per drop and batch-to-batch consistency. A calculation cannot replace physical testing.
LSD and 2C-B routines cannot simply be transferred to mescaline. No controlled human study establishes a microdosing schedule for very-low-dose VAST use, so the responsible page defines questions and boundaries—not a regimen.
INTENTION
VAST is framed around perspective and patient attention. Brand intention should never be presented as a promised outcome.
TIME HORIZON
Published higher-dose studies show a long acute arc. Low-dose timing is unknown, so a short free window should not be assumed.
DOCUMENTATION
Any future controlled development work should record the batch, delivered amount, timing, context, physiological measures and adverse events.
REST & FREQUENCY
No evidence-based interval has been established. Frequency language remains off the consumer page until supported.
NO STACKING PROTOCOL
VAST does not borrow supplement stacks from other psychedelic products. Interaction evidence is too limited for that claim.
STOPPING RULES
Concerning cardiovascular, psychological or neurological symptoms require stopping and appropriate medical assessment.
Every scientific claim on this page traces to controlled human research or official legal text. The absence of low-dose evidence stays visible.
not consumer settings.
The available safety findings come from screened participants, known compounds, defined doses, medical monitoring and emergency support. They cannot be generalized to an unverified formulation or unsupervised use.
For education only. Not medical or legal advice. For chest pain, loss of consciousness, seizure, dangerous agitation or another medical emergency, contact emergency services.